CLINICAL TRIAL: STUDY OF TAMOXIFEN AND RALOXIFENE (STAR) FOR THE PREVENTION OF B

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项针对乳腺癌风险增加的绝经后妇女的研究，她们被随机分为三苯氧胺或雷洛昔芬，以确定哪种药物最有效，副作用最少。 一项大型临床试验的证据表明，他莫昔芬有助于降低罹患乳腺癌风险增加的女性的乳腺癌发病率。美国食品和药物管理局(FDA)已批准他莫昔芬用于此类用途。雷洛昔芬已被FDA和加拿大卫生保护局(HPB)批准用于预防绝经后(已停止月经的妇女)的骨质疏松症(骨质疏松)。研究人员认为，雷洛昔芬也可能降低患乳腺癌的风险，而且副作用比他莫昔芬更少。FDA和HPB认为使用雷洛昔芬降低乳腺癌风险目前还处于实验阶段。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a study of postmenopausal women at increased risk for breast cancer who are randomized to either Tamoxifen or Raloxifene to determine which is most effective with the least amount of side effects. Evidence from a large clinical trial shows that tamoxifen helps to reduce the incidence of breast cancer in women who are at increased risk for developing the disease. The U.S. Food and Drug Administration (FDA) has approved tamoxifen for such use. Raloxifene has been approved by the FDA and the Canadian Health Protection Branch (HPB) for the prevention of osteoporosis (thinning of bones) in postmenopausal (women who have stopped menstruating). Researchers think raloxifene may also reduce the risk of developing breast cancer and have fewer side effects than tamoxifen. The FDA and the HPB consider the use of raloxifene for reducing the risk of breast cancer to be experimental at this time.